• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

NPJ Vaccines . Trends in funding for coronavirus vaccine research and development: implications for preparedness against future coronavirus threats

tetano

Editor, Senior Moderator
NPJ Vaccines


. 2026 May 26.
doi: 10.1038/s41541-026-01493-x. Online ahead of print.
Trends in funding for coronavirus vaccine research and development: implications for preparedness against future coronavirus threats

Derek Fleming[SUP] 1 [/SUP], Emily Smith[SUP] 2 [/SUP], Julie Ostrowsky[SUP] 2 [/SUP], Angela Ulrich[SUP] 2 [/SUP], Tabitha Leighton[SUP] 2 [/SUP], Natalie Vestin[SUP] 2 [/SUP], Angela J Mehr[SUP] 2 [/SUP], Rodrigo Furst[SUP] 3 [/SUP], Alice Norton[SUP] 3 [/SUP], Eve Lackritz[SUP] 2 [/SUP]


Affiliations
Free article Abstract

The COVID-19 pandemic triggered unprecedented investment in coronavirus vaccine R&D, but the long-term trajectory of this funding remains unclear. We mapped coronavirus vaccine grant support from 2020 through 2025, and found an early surge focused on ancestral SARS-CoV-2, a pivot toward broadly protective coronavirus vaccines (BPCV), and then a steep decline in publicly available funding overall, especially in the United States. Reduced sustained investment may weaken future preparedness and response globally to emergent coronavirus threats.


 
Back
Top